Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Agios Pharmaceuticals, Inc. (AGIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. As a Delaware corporation with common stock traded on the Nasdaq Global Select Market, Agios submits current and periodic reports to the U.S. Securities and Exchange Commission that document its financial condition, governance decisions, and material events.
For investors analyzing AGIO, key filings include Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s rare disease business, risk factors, research and development spending, and details on commercial-stage activities around products such as PYRUKYND (mitapivat) and AQVESME (mitapivat). Form 8-K current reports capture material developments, including quarterly financial results, stock incentive plan amendments, director elections, regulatory updates, and safety-related communications.
This page also surfaces proxy statements and exhibits referenced in filings, which can provide insight into stock incentive plans, non-employee director compensation, and shareholder voting outcomes. Where applicable, Form 4 and other ownership filings can be used to review insider transactions by directors and officers.
Stock Titan enhances these SEC documents with AI-powered summaries that explain complex sections in plain language, helping users quickly understand what each filing means for Agios’ rare disease strategy, PK activation franchise, and capital allocation. Real-time updates from EDGAR ensure that new AGIO filings appear promptly, while structured access to 10-Ks, 10-Qs, 8-Ks, and ownership reports allows for efficient due diligence on this commercial-stage biopharmaceutical company.
AGIOS PHARMACEUTICALS, INC. Chief Commercial Officer Tsveta Milanova reported a mix of equity grants, vesting, and tax-related share sales. On March 1, 2026, she received 14,000 restricted stock units and 52,000 stock options, with both awards vesting over multiple years starting March 1, 2027.
On March 2, 2026, previously granted restricted stock units vested, converting into 5,666 and 4,000 shares of common stock at no cost through derivative exercises. To cover tax withholding from these vestings, she sold 2,868 shares of common stock in open-market transactions at $28.96 per share under durable automatic Rule 10b5-1 instructions. After these trades, she continued to hold tens of thousands of shares directly.
AGIOS PHARMACEUTICALS, INC. principal accounting officer Theodore James Washburn Jr. reported multiple equity transactions linked to restricted stock units. On March 1, 2026, he received a grant of 8,452 restricted stock units, each representing a contingent right to one share of common stock, vesting in three equal annual installments beginning March 1, 2027.
On March 2, 2026, restricted stock units granted in 2023, 2024 and 2025 vested, with 2,350, 2,450 and 2,695 units respectively converting into common stock at no cost. To cover tax withholding obligations from these vestings, he sold a total of 2,223 shares of common stock in open-market transactions at $28.96 per share pursuant to durable automatic sale instructions under Rule 10b5‑1. Following these transactions, he held 6,140 common shares directly, including 75 shares acquired through the company’s employee stock purchase plan.
AGIOS PHARMACEUTICALS, INC. executive Krishnan Viswanadhan, Chief Corporate Development & Strategy, reported equity compensation grants rather than market purchases or sales. He received 14,000 restricted stock units, each representing a right to one share of common stock.
The restricted stock units were granted on March 1, 2026 and will vest in three equal annual installments beginning March 1, 2027. He was also granted stock options covering 52,000 shares at a per-share exercise price of $0.00, vesting 25% on March 1, 2027 and the remaining 75% in 36 equal monthly installments thereafter.
AGIO submitted a Form 144 disclosure concerning Common Stock, showing a scheduled vesting of Restricted Stock Units on 03/02/2026 and a prior sale by a named person. The filing lists a past sale of 18,703 shares on 12/30/2025 for $506,664.00.
The filing identifies Brian Goff as the prior seller and records the vesting event as an issuer action on 03/02/2026. Timing and cash‑flow treatment for the 03/02/2026 item are stated as vesting; sale execution details for any future disposition are not included.
AGIO filing notifies a proposed sale of 5,218 shares of common stock in connection with the vesting of restricted stock units, scheduled 03/02/2026. The filing also reports a prior sale of 2,932 shares on 12/30/2025 by James Burns.
AGIO filed a Form 144 reporting a proposed sale of 4,055 shares of common stock, tied to the vesting of restricted stock units on 03/02/2026.
Shares outstanding were 58,592,172 as of 03/02/2026. The filing also lists prior sales of 2,932 shares on 12/30/2025.
Cecilia Jones reports a proposed sale of 5,035 shares of common stock under Rule 144 tied to the vesting of Restricted Stock Units on 03/02/2026. The filing also shows 2,932 shares sold on 12/30/2025 in the prior three months.
Tsveta Milanova submitted a Form 144 notice relating to proposed sales of Common Stock and records a vesting of Restricted Stock Units on 03/02/2026 for 2,868 shares. The filing lists two recent dispositions: 2,932 shares on 12/30/2025 and 2,872 shares on 01/05/2026.
Agios Pharmaceuticals ownership filing reports that Armistice Capital, LLC and Steven Boyd together beneficially own 3,036,000 shares, representing 5.21% of Agios common stock as reported by the issuer.
The filing states the Reporting Persons have shared voting and dispositive power over those shares and that the Master Fund is the direct holder; the Master Fund disclaims beneficial ownership due to its investment management agreement with Armistice Capital.
Agios Pharmaceuticals, Inc. has filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, allowing it to offer debt securities, common stock, preferred stock, warrants and units from time to time after effectiveness. Specific terms for each issuance will be set in separate prospectus supplements.
Agios is a commercial-stage biopharmaceutical company focused on rare disease treatments, with a foundation in hematology. It plans to use any net proceeds primarily for general corporate purposes, including working capital, research and development, clinical and commercialization expenses, potential acquisitions or investments, and possible repayment or refinancing of debt.